Characterization of residues involved in soluble guanylate cyclase activation

Antonia Marazioti, George Dalkas, George Spyroulias, Andreas Papapetropoulos

Research output: Contribution to journalArticle

Abstract

Soluble guanylate cyclase (sGC) is a heterodimeric hemoprotein composed of two sub-units, α1 or α2 and β1 that plays a key role in various signal transduction pathways. The enzyme is stimulated by nitric oxide (NO) following its interaction with the heme moiety bound to the N-terminus of the β1 subunit. The aim of the present work was to identify residues in the regulatory domain of the β1 subunit that regulate the responsiveness of the enzyme on heme dependent and heme independent agonists. Molecular dynamics calculations suggested mutations to perturb the native network of electrostatic interactions at the area of Heme propionic groups. Respective mutants were generated by using site-directed mutagenesis. COS-7 cells were then co-transfected with the wild type α1 subunit and wild-type or mutated β1 subunit of sGC. The expression levels of the sGC subunits were confirmed by Western blot analysis. One of the mutants exhibited no responsiveness to neither NO nor HMR-1766, indicating that the generated enzyme was devoid of any activity. On the other hand, a residue was identified that was 45% less responsive to NO, when stimulated by sodium nitroprusside. Interestingly, cGMP generation of this latter mutant following activation by HMR-1766 was identical to that of wild-type sGC. In the present work we have identified residues that differentially affect the responsiveness to heme-NO-independent sGC activators versus NO-releasing stimulators.

Original languageEnglish (US)
Pages (from-to)56-57
Number of pages2
JournalEpitheorese Klinikes Farmakologias kai Farmakokinetikes
Volume27
Issue number1
StatePublished - May 27 2009
Externally publishedYes

Fingerprint

Heme
Nitric Oxide
Enzymes
COS Cells
Nitroprusside
Molecular Dynamics Simulation
Site-Directed Mutagenesis
Static Electricity
Signal Transduction
Western Blotting
Soluble Guanylyl Cyclase
Mutation
5-chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide

Keywords

  • HMR-1766
  • Site-directed mutagenesis
  • SNP
  • Soluble guanylate cyclase

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Characterization of residues involved in soluble guanylate cyclase activation. / Marazioti, Antonia; Dalkas, George; Spyroulias, George; Papapetropoulos, Andreas.

In: Epitheorese Klinikes Farmakologias kai Farmakokinetikes, Vol. 27, No. 1, 27.05.2009, p. 56-57.

Research output: Contribution to journalArticle

@article{59a5ee5bb7914d62b60f4a69a104d705,
title = "Characterization of residues involved in soluble guanylate cyclase activation",
abstract = "Soluble guanylate cyclase (sGC) is a heterodimeric hemoprotein composed of two sub-units, α1 or α2 and β1 that plays a key role in various signal transduction pathways. The enzyme is stimulated by nitric oxide (NO) following its interaction with the heme moiety bound to the N-terminus of the β1 subunit. The aim of the present work was to identify residues in the regulatory domain of the β1 subunit that regulate the responsiveness of the enzyme on heme dependent and heme independent agonists. Molecular dynamics calculations suggested mutations to perturb the native network of electrostatic interactions at the area of Heme propionic groups. Respective mutants were generated by using site-directed mutagenesis. COS-7 cells were then co-transfected with the wild type α1 subunit and wild-type or mutated β1 subunit of sGC. The expression levels of the sGC subunits were confirmed by Western blot analysis. One of the mutants exhibited no responsiveness to neither NO nor HMR-1766, indicating that the generated enzyme was devoid of any activity. On the other hand, a residue was identified that was 45{\%} less responsive to NO, when stimulated by sodium nitroprusside. Interestingly, cGMP generation of this latter mutant following activation by HMR-1766 was identical to that of wild-type sGC. In the present work we have identified residues that differentially affect the responsiveness to heme-NO-independent sGC activators versus NO-releasing stimulators.",
keywords = "HMR-1766, Site-directed mutagenesis, SNP, Soluble guanylate cyclase",
author = "Antonia Marazioti and George Dalkas and George Spyroulias and Andreas Papapetropoulos",
year = "2009",
month = "5",
day = "27",
language = "English (US)",
volume = "27",
pages = "56--57",
journal = "Epitheorese Klinikes Farmakologias kai Farmakokinetikes",
issn = "1011-6575",
publisher = "PHARMAKON-Press",
number = "1",

}

TY - JOUR

T1 - Characterization of residues involved in soluble guanylate cyclase activation

AU - Marazioti, Antonia

AU - Dalkas, George

AU - Spyroulias, George

AU - Papapetropoulos, Andreas

PY - 2009/5/27

Y1 - 2009/5/27

N2 - Soluble guanylate cyclase (sGC) is a heterodimeric hemoprotein composed of two sub-units, α1 or α2 and β1 that plays a key role in various signal transduction pathways. The enzyme is stimulated by nitric oxide (NO) following its interaction with the heme moiety bound to the N-terminus of the β1 subunit. The aim of the present work was to identify residues in the regulatory domain of the β1 subunit that regulate the responsiveness of the enzyme on heme dependent and heme independent agonists. Molecular dynamics calculations suggested mutations to perturb the native network of electrostatic interactions at the area of Heme propionic groups. Respective mutants were generated by using site-directed mutagenesis. COS-7 cells were then co-transfected with the wild type α1 subunit and wild-type or mutated β1 subunit of sGC. The expression levels of the sGC subunits were confirmed by Western blot analysis. One of the mutants exhibited no responsiveness to neither NO nor HMR-1766, indicating that the generated enzyme was devoid of any activity. On the other hand, a residue was identified that was 45% less responsive to NO, when stimulated by sodium nitroprusside. Interestingly, cGMP generation of this latter mutant following activation by HMR-1766 was identical to that of wild-type sGC. In the present work we have identified residues that differentially affect the responsiveness to heme-NO-independent sGC activators versus NO-releasing stimulators.

AB - Soluble guanylate cyclase (sGC) is a heterodimeric hemoprotein composed of two sub-units, α1 or α2 and β1 that plays a key role in various signal transduction pathways. The enzyme is stimulated by nitric oxide (NO) following its interaction with the heme moiety bound to the N-terminus of the β1 subunit. The aim of the present work was to identify residues in the regulatory domain of the β1 subunit that regulate the responsiveness of the enzyme on heme dependent and heme independent agonists. Molecular dynamics calculations suggested mutations to perturb the native network of electrostatic interactions at the area of Heme propionic groups. Respective mutants were generated by using site-directed mutagenesis. COS-7 cells were then co-transfected with the wild type α1 subunit and wild-type or mutated β1 subunit of sGC. The expression levels of the sGC subunits were confirmed by Western blot analysis. One of the mutants exhibited no responsiveness to neither NO nor HMR-1766, indicating that the generated enzyme was devoid of any activity. On the other hand, a residue was identified that was 45% less responsive to NO, when stimulated by sodium nitroprusside. Interestingly, cGMP generation of this latter mutant following activation by HMR-1766 was identical to that of wild-type sGC. In the present work we have identified residues that differentially affect the responsiveness to heme-NO-independent sGC activators versus NO-releasing stimulators.

KW - HMR-1766

KW - Site-directed mutagenesis

KW - SNP

KW - Soluble guanylate cyclase

UR - http://www.scopus.com/inward/record.url?scp=65749114627&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65749114627&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:65749114627

VL - 27

SP - 56

EP - 57

JO - Epitheorese Klinikes Farmakologias kai Farmakokinetikes

JF - Epitheorese Klinikes Farmakologias kai Farmakokinetikes

SN - 1011-6575

IS - 1

ER -